Henry Schein, Inc. $HSIC Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC grew its stake in shares of Henry Schein, Inc. (NASDAQ:HSIC) by 171.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 820,698 shares of the company’s stock after acquiring an additional 518,914 shares during the quarter. SG Americas Securities LLC owned about 0.70% of Henry Schein worth $62,028,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. MAI Capital Management boosted its position in shares of Henry Schein by 7.5% in the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock worth $137,000 after acquiring an additional 144 shares during the last quarter. CW Advisors LLC increased its position in Henry Schein by 2.8% during the second quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock worth $432,000 after purchasing an additional 163 shares during the last quarter. Truist Financial Corp raised its stake in Henry Schein by 3.3% during the third quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock worth $368,000 after purchasing an additional 175 shares during the period. Claret Asset Management Corp raised its stake in Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock worth $232,000 after purchasing an additional 187 shares during the period. Finally, Jain Global LLC boosted its holdings in shares of Henry Schein by 2.0% in the 3rd quarter. Jain Global LLC now owns 10,662 shares of the company’s stock valued at $708,000 after purchasing an additional 207 shares during the last quarter. 96.62% of the stock is currently owned by hedge funds and other institutional investors.

Henry Schein Stock Performance

Shares of HSIC stock opened at $74.02 on Wednesday. The company has a current ratio of 1.38, a quick ratio of 0.76 and a debt-to-equity ratio of 0.59. The company has a market cap of $8.49 billion, a PE ratio of 22.64, a P/E/G ratio of 2.20 and a beta of 0.88. The company’s fifty day simple moving average is $77.65 and its 200-day simple moving average is $73.13. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a net margin of 3.02% and a return on equity of 15.16%. The firm had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. During the same period in the prior year, the company earned $1.19 EPS. The firm’s revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities research analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Insider Buying and Selling

In other news, EVP Mark E. Mlotek sold 5,925 shares of the stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $80.80, for a total value of $478,740.00. Following the completion of the sale, the executive vice president owned 80,554 shares in the company, valued at approximately $6,508,763.20. This trade represents a 6.85% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Thomas C. Popeck sold 1,355 shares of the firm’s stock in a transaction dated Thursday, March 19th. The shares were sold at an average price of $72.79, for a total value of $98,630.45. Following the sale, the chief executive officer owned 86,182 shares in the company, valued at approximately $6,273,187.78. The trade was a 1.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 105,911 shares of company stock valued at $8,574,982. 1.14% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

HSIC has been the subject of several research reports. Wall Street Zen cut shares of Henry Schein from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 14th. JPMorgan Chase & Co. increased their target price on Henry Schein from $78.00 to $92.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 25th. Barclays started coverage on Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 price target for the company. Barrington Research set a $97.00 price target on Henry Schein and gave the stock an “outperform” rating in a research note on Wednesday, February 25th. Finally, Mizuho raised their price objective on Henry Schein from $81.00 to $88.00 and gave the stock a “neutral” rating in a report on Wednesday, February 25th. Six equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Henry Schein presently has an average rating of “Hold” and a consensus target price of $85.58.

Henry Schein Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.